2019 Industry Education

Click here to access the education, useful guidelines and symposia materials from Industry Contributors.
Includes:

2019 | SGLT-2 INHIBITOR USE IN T1D
2019 | SANOFI SYMPOSIA

This information has been developed for HCPs regarding the use of Dapagliflozin as adjunct therapy in Adults with Type 1 Diabetes.

This online education was developed with an unrestricted medical education grant from AstraZeneca and is a medical information resource intended for healthcare professionals, outside of the USA and specifically in Europe, who are interested in medical information related to the use of Dapagliflozin as adjunct therapy in Adults with Type 1 Diabetes. The following resources are shared as medical information only and are not issued as medical advice from ATTD or Astra Zeneca.

Please click Enter Course to access the following content:

1. Materials for Endocrinologists / Diabetologists

2. Materials for HCP 'Peer-to-Peer' Education (feat. touchIME online media)

3. Patient Education

Enter course

SANOFI AT ATTD 2019

At the 12^th International Conference on Advanced Treatments for Diabetes (ATTD) in Berlin, Germany, Sanofi offered timely insights into the latest advances in clinical care. Our key symposia at the congress offered delegates an opportunity to see the latest data and hear expert opinion on a range of topics from continuous glucose monitoring to integrated care solutions.

Please click Enter Course to access the video content and the relevant ePosters from this event.

Enter course